Register
Login:
Share:
Email Facebook Twitter

Member Info for bigbob0228


Member Since: Mon, 7th Apr 2008

Number of Share Chat Posts (all time): 101
Number of Share Chat Posts (last 30 days): 6

Last Posted: Fri 17:11


Post Distribution over the last 30 days




Fri 17:11


Many thanks excellent explanation.

GL All

Bob
Fri 16:45


Can someone explain 98m at 58.2 UT at 1635.03 ?
2 Dec '14


GW Pharmaceuticals boss: Cannabis-based treatments could be used in autism

Telegraph

By Denise Roland | Telegraph – 3 hours ago

Share1Tweet

Print

Companies:

GW Pharmaceuticals plc

RELATED QUOTES

Symbol Price Change

GWPH 71.3999 -0.2301

Justin Gover says GW's experimental drug for severe epilepsy also appears to treat symptoms of autism

GW Pharmaceuticals (NasdaqGM: GWPH - news) is to investigate whether a cannabis-based medicine could treat symptoms of severe autism.

The British drugmaker, which develops medicines using cannabis extracts, is putting together the "building blocks" of a research programme into autism, its chief executive told The Telegraph.

Justin Gover said doctors treating severely epileptic children with GW's experimental drug Epidiolex had observed improvements in behaviour and brain function in those patients who also had autism.

He cautioned that the observations were "no more scientific at this stage" but that he saw an "important role for GW in researching the use of cannabinoids within autism-like disorders".

GW has been testing Epidiolex in a few dozen children with debilitating forms of epilepsy in the US for around a year and has already seen "promising" results . It has done so under a so-called "expanded access" programme which allows patients with untreatable conditions to try out experimental drugs.

It recently embarked on a formal clinical trial of the drug across Europe and the US, which includes patients at Great Ormond Street Hospital in London. GW hopes to complete clinical trials by the middle of 2016 and launch Epidiolex in early 2017.

Analysts have previously suggested that Epidiolex could also be used in autism since the two conditions are closely associated. As many as a third of people on the autistic spectrum also have epilepsy. A recent study by scientists at Stanford University in California also suggested that compounds found in cannabis could successfully treat autism.

Mr Gover revealed his new research plans as GW released its full-year results showing losses widened to £14.7m in the year to September 30. These compared with a loss of £4.9m a year earlier and largely due to the company ploughing money into its Epidiolex programme, it said.

GW also posted a 10pc increase in full-year revenues to £30m, driven by a doubling in sales of the company's single product Sativex, which treats pain in multiple sclerosis, from £2.2m to £4.4m.

The group makes most of its income from fees charged to Japanese drug maker Otsuka, which has secured the exclusive rights to develop and market Sativex in the US. GW said Otsuka paid it £24.3m in the year to September 30 for its work in getting Sativex - which is currently unavailable in the US - approved for use in cancer pain.
1 Dec '14


we should find out 1pm tomorrow IMO tree shaking trying to trigger stop losses good results and could be back to $90 by fridays close

GL All
25 Nov '14


Nearly 2.5 million shares bought between 16.35 and 16.52 after hours on the FTSE Aim market wonder if thats a omen for 2nd December.


Sign up for Live Prices
Top Recommended
Hot Chat Topics
Top recommended posters in the last 30 days
Share Price Spaceronceatrader1006 
Share Price SpacerK3VMC834 
Share Price SpacerBrotherhumble699 
Share Price SpacerGrumpyScouser566 
Share Price Spacertwgweenyteeth507 
Share Price Spacerrobbajob494 
Share Price SpacerLiquid_Gold478 
Share Price Spacerokenia438 




Member Login

Forgotten your password?
Email:

Password:


Don't have an account? Click here to Register Free!


Home  |  Contact Us  |  About Us  |  Careers  |  Advertise with Us  |  Sitemap  |  Terms & Conditions  |  Cookies  |  Privacy


Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.